AggreDyne, Inc. is a privately held Houston, Texas medical device and in vitro diagnostics manufacturer, founded in 2011 by Edward R. Teitel, MD, JD and Robert C. Hux, CPA, to commercialize the AggreGuide platelet function analyzer. Its flagship product, the AggreGuide A-100, is a benchtop laser light scattering aggregometer that measures platelet aggregation from a single-use disposable cartridge in under five minutes, assessing how well a patient is responding to antiplatelet therapy such as aspirin, clopidogrel, prasugrel and ticagrelor. The company holds three FDA 510(k) clearances under product code JOZ — K122162 (2013), K163274 for the A-100 AA Assay and Instrument (2017), and K181777 for the A-100 ADP assay cartridge (2019) — and its products are CE marked. It sells to hospital laboratories, physician office laboratories in cardiology, endocrinology, neurology and family practice, and regional reference laboratories. AggreDyne is a diagnostic instrument and consumable manufacturer rather than a software or platform business: it has never published a developer program, public API, SDK, or machine-readable API contract, and as of September 2026 its corporate website is offline behind a suspended hosting account.
AggreDyne is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Diagnostics, In Vitro Diagnostics, and Healthcare.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/aggredyne: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: aggredyne
name: AggreDyne
description: 'AggreDyne, Inc. is a privately held Houston, Texas medical device and in vitro diagnostics manufacturer, founded
in 2011 by Edward R. Teitel, MD, JD and Robert C. Hux, CPA, to commercialize the AggreGuide platelet function analyzer.
Its flagship product, the AggreGuide A-100, is a benchtop laser light scattering aggregometer that measures platelet aggregation
from a single-use disposable cartridge in under five minutes, assessing how well a patient is responding to antiplatelet
therapy such as aspirin, clopidogrel, prasugrel and ticagrelor. The company holds three FDA 510(k) clearances under product
code JOZ — K122162 (2013), K163274 for the A-100 AA Assay and Instrument (2017), and K181777 for the A-100 ADP assay cartridge
(2019) — and its products are CE marked. It sells to hospital laboratories, physician office laboratories in cardiology,
endocrinology, neurology and family practice, and regional reference laboratories. AggreDyne is a diagnostic instrument
and consumable manufacturer rather than a software or platform business: it has never published a developer program, public
API, SDK, or machine-readable API contract, and as of September 2026 its corporate website is offline behind a suspended
hosting account.'
url: https://raw.githubusercontent.com/api-evangelist/aggredyne/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-12'
modified: '2026-09-12'
tags:
- Company
- Medical Devices
- Diagnostics
- In Vitro Diagnostics
- Healthcare
- Hematology
- Platelet Function Testing
- Laboratory
- Manufacturing
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/aggredyne-domain-security.yml
- type: Website
url: https://www.aggredyne.com/
- type: LinkedIn
url: https://www.linkedin.com/company/aggredyne
- type: Regulatory
url: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K181777
x-enrichment:
date: '2026-09-12'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 'AggreDyne sells a benchtop laser light scattering platelet aggregometer and its single-use cartridges — an FDA
510(k) class of physical in vitro diagnostic goods (K122162, K163274, K181777, all product code JOZ), not software — and
there is no developer program, GitHub organization (github.com/aggredyne is a hard 404, and a GitHub code search for "aggredyne"
returns zero repositories) or integration surface of any kind attached to it. The company surface could not be walked
live either: the aggredyne.com hosting account is SUSPENDED, so the origin answers every path on both aggredyne.com and
www.aggredyne.com with an identical 7,768-byte cPanel "Account Suspended" page (plain HTTP 302s to /cgi-sys/suspendedpage.cgi),
and its Let''s Encrypt certificate, CN=cpanel.aggredyne.com, expired on 2026-05-15. That catch-all makes the HTTP 200
on every REST, GraphQL, MCP, agent-card, llms.txt and /.well-known/ probe a false positive — a random control path returns
byte-identical content — so all sixteen well-known probes are recorded as misses and no WellKnown, SecurityTxt or AgentCard
pointer was wired. The api./app./portal./developer./cloud. subdomains resolve only to the same shared cPanel wildcard
IP 162.253.33.192, not to distinct surfaces. The harvest lead''s original Website pointer, https://www.nasdaqprivatemarket.com/,
was the secondary-market platform''s own home page rather than this company''s site and has been removed.'
evidence:
- url: http://www.aggredyne.com/
status: 302
- url: https://www.aggredyne.com/
status: 200
- url: https://www.aggredyne.com/this-path-does-not-exist-zzz9876
status: 200
- url: https://www.aggredyne.com/openapi.json
status: 200
- url: https://www.aggredyne.com/swagger.json
status: 200
- url: https://www.aggredyne.com/graphql
status: 200
- url: https://www.aggredyne.com/llms.txt
status: 200
- url: https://www.aggredyne.com/.well-known/agent-card.json
status: 200
- url: https://aggredyne.com/.well-known/api-catalog
status: 200
- url: https://aggredyne.com/.well-known/security.txt
status: 200
- url: https://github.com/aggredyne
status: 404
- url: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K181777
status: 200
checked: '2026-09-12'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →